New Australian Study Shows Teen E-Cigarette Use on the Rise

Sep.28.2022
New Australian Study Shows Teen E-Cigarette Use on the Rise
Australian study reveals vaping is easy for teens to access, with taste being the primary factor in product selection.

A recent study, published in the Australian and New Zealand Journal of Public Health, has shown that nearly 80% of teenagers who use e-cigarettes find it "very easy" to obtain them from multiple illegal sources, while taste is the main factor driving product selection. This is the first study of its kind in Australia.


The University of Sydney's Centre and the University of Sydney are conducting a leading research project, supported by the Minderoo Foundation, aimed at investigating the experiences and opinions of teenagers towards e-cigarettes in Australia.


A survey has found that 70% of teenage e-cigarette users obtain the products for free from individuals, while 30% purchase them themselves from "friends" or commercial retail stores such as convenience stores and tobacco shops. Teenagers also reported purchasing e-cigarettes through social media, e-cigarette stores, and websites.


The committee stated that the investigation results indicate that the government's control measures aimed at protecting young people from the harms of e-cigarettes have failed.


Regardless of how teenagers obtain electronic cigarettes, they are all illegal, and yet it is happening right under the noses of federal and state authorities," Ms. Desai said. "All Australian governments have stated that they are committed to ensuring that only smokers attempting to quit with a prescription can use e-cigarettes. However, a crisis of teenage e-cigarette use is looming.


The widespread illicit use of e-cigarettes among young people, coupled with the import, retail and wholesale sales of these products, has escalated from an urgent concern to a crisis. According to Becky Freeman, the lead researcher and associate professor at the University of Sydney, the findings reflect how e-cigarettes are marketed and promoted to the youth market.


According to the survey, 32% of adolescents surveyed have tried electronic cigarettes by taking at least a few puffs. Of those who have tried e-cigarettes, more than half had never smoked tobacco before," said Professor Freeman.


Ruby Ellis, a 17-year-old teenager from New South Wales, has been vaping for three years. She acknowledges that she knew it was addictive when she first started, but didn't fully grasp the intensity of addiction until she succumbed to it herself. "Prior to being addicted, you don't really understand the full implications of addiction and how it impacts you," she said.


Ruby is just one of many people in New South Wales who currently vape and describe it as being available anytime, anywhere. "It's always around, whether someone is having a cup of coffee, studying, or even taking a break in the restroom.


Ms. Dessaix stated that urgent action is needed to effectively enforce regulations and protect all young Australians from the harm of e-cigarettes.


Statement:


This article is compiled from third-party information and is intended for industry communication and learning purposes only.


This article does not reflect the views of 2FIRSTS, and 2FIRSTS is unable to confirm the authenticity or accuracy of the article's content. The translation of this article is solely intended for industry exchange and research.


Due to limitations in translation ability, the translated article may not necessarily convey the same meaning as the original. Please refer to the original article for accuracy.


2FIRSTS adheres completely to the positions and statements of the Chinese government on all matters related to domestic issues, as well as those involving Hong Kong, Macau, Taiwan, and foreign affairs.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
At the 2026 NACS Show in Las Vegas, JTI Liggett highlighted its value-priced cigarette portfolio, including LD and Montego, following JT Group's acquisition of Vector Group. The company's U.S. business reported market share gains, with LD sales volume rising 32.6% in the first half of 2026. Meanwhile, Ploom was displayed separately at Altria's booth under an existing partnership. JTI Liggett booth staff told 2Firsts that the company had not yet launched nicotine pouch products in the United States.
EXPO
Oct.09
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
The Bombay High Court has ruled that airport duty-free shops are not exempt from India's domestic regulatory laws merely because they operate beyond the customs barrier, leaving in place a sales halt covering ZYN and FOX nicotine pouches at Mumbai's international airport. The court, however, did not determine that the products necessarily qualify as "drugs" under India's Drugs and Cosmetics Act. The retailers have four weeks to submit product information to the appropriate authorities, including CDSCO, which must complete its review within 30 days of receiving the submissions.
Sep.24
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
Following recent FDA authorizations for JUUL2 and ZYN ULTRA, 2Firsts Compliance Solutions held an online PMTA briefing on Sept. 4 to examine what the decisions may signal about review efficiency, scientific evidence and U.S. market access. Nearly 30 participants from brands, manufacturers, compliance service providers and investment firms joined the discussion.
2Firsts Events
Sep.06
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
Altria Showcases Ploom, Marlboro Heated Tobacco Sticks and Non-Nicotine Energy Products at NACS Show 2026
Altria Showcases Ploom, Marlboro Heated Tobacco Sticks and Non-Nicotine Energy Products at NACS Show 2026
At the 2026 NACS Show, Altria displayed Ploom devices alongside imagery of Marlboro-branded heated tobacco sticks, while also featuring RIOT Energy and Proper Wild non-nicotine products. The booth showcased on! PLUS nicotine pouches, including 12 mg variants not listed among FDA-authorized products as of October 9, and NJOY e-cigarettes. Altria also presented convenience-store traffic figures highlighting its retail presence. 2Firsts examines the company's expanded product portfolio, non-nicotine business activities and the regulatory status of products displayed at the show.
EXPO
Oct.10